Lexaria Bioscience Corp. (LEXX)
USD 1.43
(-6.54%)
USD 1.43
(-6.54%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.08 Million USD | -60.63% |
| 2022 | 7.83 Million USD | -40.95% |
| 2021 | 13.26 Million USD | 369.08% |
| 2020 | 2.82 Million USD | 5.72% |
| 2019 | 2.67 Million USD | 10.01% |
| 2018 | 2.43 Million USD | -14.98% |
| 2017 | 2.86 Million USD | 404.76% |
| 2016 | 566.63 Thousand USD | -20.38% |
| 2015 | 711.72 Thousand USD | -80.08% |
| 2014 | 3.57 Million USD | -14.75% |
| 2013 | 4.19 Million USD | -3.4% |
| 2012 | 4.33 Million USD | 32.37% |
| 2011 | 3.27 Million USD | -1.53% |
| 2010 | 3.32 Million USD | -11.53% |
| 2009 | 3.76 Million USD | -0.87% |
| 2008 | 3.79 Million USD | 39.59% |
| 2007 | 2.71 Million USD | 147.09% |
| 2006 | 1.1 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 6.35 Million USD | 75.14% |
| 2024 Q3 | 10.01 Million USD | 57.72% |
| 2024 Q1 | 3.62 Million USD | 17.6% |
| 2023 Q1 | 6.21 Million USD | -20.68% |
| 2023 FY | 3.08 Million USD | -60.63% |
| 2023 Q3 | 5.23 Million USD | 7.92% |
| 2023 Q4 | 3.08 Million USD | -41.14% |
| 2023 Q2 | 4.85 Million USD | -21.86% |
| 2022 Q4 | 7.83 Million USD | -14.27% |
| 2022 Q1 | 11.74 Million USD | -11.46% |
| 2022 Q2 | 11.41 Million USD | -2.82% |
| 2022 Q3 | 9.13 Million USD | -19.94% |
| 2022 FY | 7.83 Million USD | -40.95% |
| 2021 FY | 13.26 Million USD | 369.08% |
| 2021 Q2 | 12.17 Million USD | 459.83% |
| 2021 Q3 | 10.54 Million USD | -13.35% |
| 2021 Q1 | 2.17 Million USD | -23.12% |
| 2021 Q4 | 13.26 Million USD | 25.78% |
| 2020 Q4 | 2.82 Million USD | -14.82% |
| 2020 Q2 | 1.98 Million USD | -27.67% |
| 2020 Q3 | 3.32 Million USD | 67.16% |
| 2020 FY | 2.82 Million USD | 5.72% |
| 2020 Q1 | 2.74 Million USD | 2.65% |
| 2019 Q4 | 2.67 Million USD | -22.62% |
| 2019 Q2 | 4.27 Million USD | 20.58% |
| 2019 Q1 | 3.54 Million USD | 45.74% |
| 2019 Q3 | 3.45 Million USD | -19.1% |
| 2019 FY | 2.67 Million USD | 10.01% |
| 2018 Q4 | 2.43 Million USD | -10.23% |
| 2018 Q2 | 2.84 Million USD | 13.78% |
| 2018 FY | 2.43 Million USD | -14.98% |
| 2018 Q1 | 2.49 Million USD | -12.69% |
| 2018 Q3 | 2.7 Million USD | -4.65% |
| 2017 Q4 | 2.86 Million USD | -9.04% |
| 2017 Q3 | 3.14 Million USD | 261.78% |
| 2017 Q2 | 869.11 Thousand USD | -23.55% |
| 2017 Q1 | 1.13 Million USD | 100.64% |
| 2017 FY | 2.86 Million USD | 404.76% |
| 2016 Q4 | 566.63 Thousand USD | 71.06% |
| 2016 FY | 566.63 Thousand USD | -20.38% |
| 2016 Q3 | 331.25 Thousand USD | -14.94% |
| 2016 Q2 | 389.43 Thousand USD | -21.5% |
| 2016 Q1 | 496.11 Thousand USD | -30.29% |
| 2015 FY | 711.72 Thousand USD | -80.08% |
| 2015 Q1 | 2.25 Million USD | -50.7% |
| 2015 Q2 | 1.21 Million USD | -46.23% |
| 2015 Q3 | 1.19 Million USD | -0.96% |
| 2015 Q4 | 711.72 Thousand USD | -40.63% |
| 2014 FY | 3.57 Million USD | -14.75% |
| 2014 Q1 | 3.57 Million USD | -2.98% |
| 2014 Q3 | 4.83 Million USD | 35.9% |
| 2014 Q4 | 4.56 Million USD | -5.61% |
| 2014 Q2 | 3.55 Million USD | -0.39% |
| 2013 Q3 | 3.79 Million USD | -3.16% |
| 2013 Q1 | 4.19 Million USD | -0.77% |
| 2013 FY | 4.19 Million USD | -3.4% |
| 2013 Q4 | 3.68 Million USD | -3.06% |
| 2013 Q2 | 3.92 Million USD | -6.41% |
| 2012 Q2 | 4.22 Million USD | -2.56% |
| 2012 Q4 | 4.22 Million USD | 2.25% |
| 2012 Q3 | 4.13 Million USD | -2.3% |
| 2012 FY | 4.33 Million USD | 32.37% |
| 2012 Q1 | 4.33 Million USD | 12.28% |
| 2011 FY | 3.27 Million USD | -1.53% |
| 2011 Q1 | 3.27 Million USD | -4.1% |
| 2011 Q2 | 3.71 Million USD | 13.37% |
| 2011 Q3 | 3.51 Million USD | -5.47% |
| 2011 Q4 | 3.86 Million USD | 10.0% |
| 2010 Q4 | 3.41 Million USD | 2.36% |
| 2010 Q3 | 3.33 Million USD | -1.74% |
| 2010 Q1 | 3.32 Million USD | 2.43% |
| 2010 Q2 | 3.39 Million USD | 2.08% |
| 2010 FY | 3.32 Million USD | -11.53% |
| 2009 Q1 | 3.76 Million USD | -1.45% |
| 2009 FY | 3.76 Million USD | -0.87% |
| 2009 Q4 | 3.25 Million USD | 0.95% |
| 2009 Q3 | 3.21 Million USD | -5.03% |
| 2009 Q2 | 3.39 Million USD | -9.91% |
| 2008 Q3 | 3.59 Million USD | -15.03% |
| 2008 Q1 | 3.79 Million USD | 18.97% |
| 2008 Q4 | 3.81 Million USD | 6.08% |
| 2008 Q2 | 4.23 Million USD | 11.61% |
| 2008 FY | 3.79 Million USD | 39.59% |
| 2007 Q3 | 2.43 Million USD | -1.45% |
| 2007 FY | 2.71 Million USD | 147.09% |
| 2007 Q2 | 2.47 Million USD | -8.97% |
| 2007 Q1 | 2.71 Million USD | 144.17% |
| 2007 Q4 | 3.19 Million USD | 30.79% |
| 2006 Q3 | 1.16 Million USD | -2.37% |
| 2006 FY | 1.1 Million USD | 0.0% |
| 2006 Q4 | 1.11 Million USD | -4.31% |
| 2006 Q2 | 1.19 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 99.793% |
| Alkermes plc | 2.13 Billion USD | 99.856% |
| Agenus Inc. | 313.91 Million USD | 99.018% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 99.919% |
| Aptorum Group Limited | 20.64 Million USD | 85.058% |
| Ardelyx, Inc. | 297.57 Million USD | 98.964% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 99.597% |
| Bicycle Therapeutics plc | 595.34 Million USD | 99.482% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | 95.816% |
| ChromaDex Corporation | 54.96 Million USD | 94.389% |
| Chimerix, Inc. | 212.77 Million USD | 98.551% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | 89.092% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 99.301% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 99.862% |
| Precision BioSciences, Inc. | 159.78 Million USD | 98.07% |
| Dyadic International, Inc. | 8.21 Million USD | 62.478% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | 90.284% |
| Fortress Biotech, Inc. | 167.52 Million USD | 98.159% |
| Lantern Pharma Inc. | 43.64 Million USD | 92.934% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | 98.088% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | 78.741% |
| Incyte Corporation | 6.78 Billion USD | 99.955% |
| IO Biotech, Inc. | 150.71 Million USD | 97.954% |
| Jaguar Health, Inc. | 50.76 Million USD | 93.925% |
| Novavax, Inc. | 1.85 Billion USD | 99.834% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 99.189% |
| Opthea Limited | 188.79 Million USD | 98.366% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 99.63% |
| ContextLogic Inc. | 423 Million USD | 99.271% |
| MiMedx Group, Inc. | 239.04 Million USD | 98.71% |
| Pyxis Oncology, Inc. | 173.72 Million USD | 98.225% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | 40.345% |
| NextCure, Inc. | 129.41 Million USD | 97.617% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | 94.283% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | 91.603% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | 90.452% |
| Vaxcyte, Inc. | 1.4 Billion USD | 99.781% |
| PDS Biotechnology Corporation | 59.39 Million USD | 94.807% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 99.519% |
| Pharming Group N.V. | 462.85 Million USD | 99.334% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | 92.027% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 99.509% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 83.703% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | 83.703% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 98.135% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | 93.19% |
| Acelyrin, Inc. | 742.69 Million USD | 99.585% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | 53.177% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | 51.835% |
| Summit Therapeutics Inc. | 202.94 Million USD | 98.48% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | 95.853% |
| Senti Biosciences, Inc. | 119.48 Million USD | 97.419% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | 98.649% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | 98.166% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | 62.677% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | 35.397% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 99.343% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | 97.506% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 98.878% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 99.348% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 69.481% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | 98.562% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -172.399% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 99.255% |
| Immix Biopharma, Inc. | 19.92 Million USD | 84.522% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 99.167% |
| MEI Pharma, Inc. | 41.37 Million USD | 92.546% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 90.483% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 99.095% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | 97.369% |
| Fortress Biotech, Inc. | 167.52 Million USD | 98.159% |
| Precigen, Inc. | 151.04 Million USD | 97.958% |
| Clearside Biomedical, Inc. | 34.01 Million USD | 90.934% |
| AlloVir, Inc. | 190.79 Million USD | 98.384% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 99.181% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 99.391% |
| ImmuCell Corporation | 43.8 Million USD | 92.96% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 99.525% |
| Onconetix, Inc. | 88.82 Million USD | 96.528% |
| PureTech Health plc | 693.97 Million USD | 99.556% |
| VYNE Therapeutics Inc. | 97.68 Million USD | 96.843% |
| Elevation Oncology, Inc. | 89.09 Million USD | 96.538% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | 50.274% |
| Seer, Inc. | 436.26 Million USD | 99.293% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | 96.22% |
| Innoviva, Inc. | 1.24 Billion USD | 99.752% |
| Aadi Bioscience, Inc. | 132.42 Million USD | 97.671% |
| ESSA Pharma Inc. | 149.12 Million USD | 97.932% |
| GlycoMimetics, Inc. | 45.31 Million USD | 93.195% |
| GT Biopharma, Inc. | 14.1 Million USD | 78.142% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 98.998% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 98.724% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 99.346% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | 93.917% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | 96.761% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -388.291% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 99.455% |
| Aptose Biosciences Inc. | 12.92 Million USD | 76.135% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | 86.054% |
| Soligenix, Inc. | 9.79 Million USD | 68.522% |
| Century Therapeutics, Inc. | 360.69 Million USD | 99.145% |
| Kura Oncology, Inc. | 448.93 Million USD | 99.313% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 98.867% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | 82.168% |
| Ocean Biomedical, Inc. | 110.91 Million USD | 97.219% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | 98.497% |
| Autolus Therapeutics plc | 375.38 Million USD | 99.178% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 98.774% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 99.132% |
| Eterna Therapeutics Inc. | 49.13 Million USD | 93.723% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 99.534% |
| GRI Bio, Inc. | 2.95 Million USD | -4.33% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | 70.92% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | 98.191% |
| IGM Biosciences, Inc. | 423.41 Million USD | 99.272% |
| INmune Bio, Inc. | 57 Million USD | 94.59% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 98.614% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 96.326% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 88.192% |
| Entero Therapeutics, Inc. | 6.88 Million USD | 55.195% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | 95.9% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | 97.906% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 98.137% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 99.51% |
| Verastem, Inc. | 149.71 Million USD | 97.94% |
| Abeona Therapeutics Inc. | 64 Million USD | 95.181% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 99.398% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | 98.003% |
| Histogen Inc. | 19.07 Million USD | 83.831% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | 86.384% |
| Surrozen, Inc. | 46.08 Million USD | 93.307% |
| Organovo Holdings, Inc. | 6.34 Million USD | 51.426% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | 28.423% |
| Ovid Therapeutics Inc. | 144.02 Million USD | 97.859% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 73.869% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | 95.903% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | 63.8% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 99.15% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | 82.956% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 99.282% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | 75.547% |
| Apollomics, Inc. | 55.38 Million USD | 94.432% |
| Amarin Corporation plc | 831.68 Million USD | 99.629% |
| Mesoblast Limited | 669.15 Million USD | 99.539% |
| Turnstone Biologics Corp. | 112.81 Million USD | 97.266% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 99.464% |
| Synaptogenix, Inc. | 31.11 Million USD | 90.088% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | 74.688% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 99.437% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | 47.482% |
| Monopar Therapeutics Inc. | 7.34 Million USD | 58.013% |
| Exelixis, Inc. | 2.94 Billion USD | 99.895% |
| Better Therapeutics, Inc. | 22.94 Million USD | 86.558% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 99.154% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 99.609% |
| NLS Pharmaceutics AG | 1.84 Million USD | -67.005% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | 61.347% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 79.013% |
| Gritstone bio, Inc. | 177.76 Million USD | 98.265% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 96.767% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | 82.735% |
| Avid Bioservices, Inc. | 336.55 Million USD | 99.084% |
| Insmed Incorporated | 1.32 Billion USD | 99.768% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | 67.97% |
| MediWound Ltd. | 66.45 Million USD | 95.36% |
| OmniAb, Inc. | 401.98 Million USD | 99.233% |
| Alector, Inc. | 621.82 Million USD | 99.504% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 99.14% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | 42.656% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 94.56% |
| Zai Lab Limited | 1.03 Billion USD | 99.702% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 99.355% |
| Aura Biosciences, Inc. | 255.07 Million USD | 98.791% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 99.589% |
| Immunic, Inc. | 54.29 Million USD | 94.32% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 98.842% |
| Veracyte, Inc. | 1.13 Billion USD | 99.729% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | 73.915% |
| FibroGen, Inc. | 423.52 Million USD | 99.272% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | 12.212% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | 34.89% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | 43.199% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 99.973% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | 64.975% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 99.404% |
| TG Therapeutics, Inc. | 329.58 Million USD | 99.064% |
| Galecto, Inc. | 38.22 Million USD | 91.932% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 89.245% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 99.929% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 98.69% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | 87.586% |
| XBiotech Inc. | 227.24 Million USD | 98.643% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 96.767% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | 97.837% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 98.921% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | 97.588% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 99.193% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 99.793% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 99.155% |
| Vaxxinity, Inc. | 44.35 Million USD | 93.047% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 99.403% |
| Gain Therapeutics, Inc. | 18.6 Million USD | 83.428% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 98.989% |
| NexImmune, Inc. | 8.59 Million USD | 64.114% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | 71.219% |
| Marker Therapeutics, Inc. | 17.12 Million USD | 81.994% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.991% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | 86.078% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -686.2% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | 98.221% |
| Ainos, Inc. | 31.84 Million USD | 90.315% |
| Pluri Inc. | 39.52 Million USD | 92.198% |
| Prothena Corporation plc | 696.38 Million USD | 99.557% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 98.909% |
| Celularity Inc. | 143.88 Million USD | 97.857% |
| Rallybio Corporation | 115.62 Million USD | 97.333% |
| Cue Biopharma, Inc. | 61.53 Million USD | 94.988% |
| MeiraGTx Holdings plc | 458.16 Million USD | 99.327% |
| Omeros Corporation | 378.26 Million USD | 99.185% |
| Humacyte, Inc. | 128.22 Million USD | 97.595% |
| Immunocore Holdings plc | 597 Million USD | 99.483% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | 90.134% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | 95.5% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 99.706% |
| CalciMedica, Inc. | 12.18 Million USD | 74.69% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 98.784% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | 98.196% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 99.008% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 99.454% |
| Pulmatrix, Inc. | 33.95 Million USD | 90.918% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | 88.639% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | 97.811% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 99.763% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | 97.631% |
| Cytokinetics, Incorporated | 824.31 Million USD | 99.626% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 85.4% |
| Nutriband Inc. | 7.51 Million USD | 58.974% |
| Protara Therapeutics, Inc. | 78.95 Million USD | 96.094% |
| Vor Biopharma Inc. | 209.82 Million USD | 98.53% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 99.957% |
| Evogene Ltd. | 51.1 Million USD | 93.965% |
| ProKidney Corp. | 420.55 Million USD | 99.267% |
| Applied Therapeutics, Inc. | 54.83 Million USD | 94.376% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | 67.606% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 99.436% |
| CorMedix Inc. | 82.05 Million USD | 96.242% |
| BioLineRx Ltd. | 63.92 Million USD | 95.176% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 99.234% |
| Galectin Therapeutics Inc. | 28.2 Million USD | 89.064% |
| Atai Life Sciences N.V. | 293.47 Million USD | 98.949% |
| Renovaro Biosciences Inc. | 163.12 Million USD | 98.109% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | 97.58% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 99.451% |
| Sagimet Biosciences Inc. | 96.71 Million USD | 96.811% |
| MediciNova, Inc. | 66.26 Million USD | 95.346% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | 96.493% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | 30.889% |
| GeoVax Labs, Inc. | 9.28 Million USD | 66.779% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 99.476% |
| Biomea Fusion, Inc. | 199.92 Million USD | 98.457% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 99.838% |
| Mereo BioPharma Group plc | 66.49 Million USD | 95.362% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 99.364% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 99.497% |
| Absci Corporation | 234.48 Million USD | 98.685% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | 57.84% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 99.093% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | 98.132% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 99.414% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 98.889% |
| Allakos Inc. | 243.61 Million USD | 98.734% |
| Imunon, Inc. | 21.91 Million USD | 85.929% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 98.803% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 99.504% |
| BioAtla, Inc. | 119.65 Million USD | 97.423% |
| NLS Pharmaceutics AG | 1.84 Million USD | -67.005% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | 4.224% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 99.52% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | 96.785% |
| XOMA Corporation | 234.3 Million USD | 98.684% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | 98.606% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 97.549% |
| aTyr Pharma, Inc. | 122.06 Million USD | 97.474% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | 97.996% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 99.469% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 99.371% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | 97.208% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | 79.654% |
| Akari Therapeutics, Plc | 4.35 Million USD | 29.185% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 81.899% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 99.822% |
| UroGen Pharma Ltd. | 178.31 Million USD | 98.27% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 99.345% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -454.958% |
| Orgenesis Inc. | 14.55 Million USD | 78.807% |
| Entera Bio Ltd. | 11.76 Million USD | 73.787% |
| GH Research PLC | 226.3 Million USD | 98.637% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | 94.361% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | 97.129% |
| Xencor, Inc. | 952.69 Million USD | 99.676% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | 60.379% |
| Replimune Group, Inc. | 487.72 Million USD | 99.368% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | 61.79% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 99.524% |
| Lexaria Bioscience Corp. | 3.08 Million USD | 0.0% |
| Portage Biotech Inc. | 7.77 Million USD | 60.355% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | 30.889% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 98.886% |
| OncoCyte Corporation | 74.89 Million USD | 95.882% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -51.678% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | 46.705% |
| Purple Biotech Ltd. | 44.3 Million USD | 93.039% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | 90.963% |
| scPharmaceuticals Inc. | 94.47 Million USD | 96.736% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | 82.909% |
| HilleVax, Inc. | 344.43 Million USD | 99.105% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | 2.897% |
| Tharimmune, Inc. | 10.94 Million USD | 71.826% |
| Genprex, Inc. | 10.67 Million USD | 71.098% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 99.378% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | 96.796% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -27.122% |
| Virios Therapeutics, Inc. | 4.16 Million USD | 25.963% |
| OKYO Pharma Limited | 1.54 Million USD | -100.095% |
| Savara Inc. | 177.56 Million USD | 98.263% |
| Curis, Inc. | 77.28 Million USD | 96.009% |
| Daré Bioscience, Inc. | 21.28 Million USD | 85.509% |
| Carmell Therapeutics Corporation | 63.94 Million USD | 95.177% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | 61.86% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | 84.079% |
| BeiGene, Ltd. | 5.8 Billion USD | 99.947% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 74.657% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 99.852% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 99.138% |
| Erasca, Inc. | 395.29 Million USD | 99.22% |
| bluebird bio, Inc. | 619.16 Million USD | 99.502% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | 28.667% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.955% |
| DBV Technologies S.A. | 182.98 Million USD | 98.315% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | 28.667% |
| Moderna, Inc. | 18.42 Billion USD | 99.983% |
| Vincerx Pharma, Inc. | 18.21 Million USD | 83.071% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | 73.382% |
| Molecular Templates, Inc. | 35.38 Million USD | 91.284% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | 97.77% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 99.609% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 98.985% |
| Spruce Biosciences, Inc. | 103.94 Million USD | 97.033% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 99.338% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 99.016% |
| MacroGenics, Inc. | 306.82 Million USD | 98.995% |
| RenovoRx, Inc. | 1.46 Million USD | -110.367% |
| Adicet Bio, Inc. | 207.29 Million USD | 98.512% |
| Prime Medicine, Inc. | 193.85 Million USD | 98.409% |
| Aditxt, Inc. | 44.57 Million USD | 93.082% |
| Adagene Inc. | 115.72 Million USD | 97.335% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | 30.762% |
| Quantum-Si incorporated | 298.25 Million USD | 98.966% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 99.793% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | 59.996% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 99.122% |
| SciSparc Ltd. | 11.18 Million USD | 72.42% |
| Vericel Corporation | 353.65 Million USD | 99.128% |
| Revelation Biosciences, Inc. | 12.21 Million USD | 74.748% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | 94.58% |
| Generation Bio Co. | 374.75 Million USD | 99.177% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 98.789% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | 98.055% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 99.097% |
| Invivyd, Inc. | 229.18 Million USD | 98.654% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 99.635% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | 74.658% |
| Spero Therapeutics, Inc. | 182.39 Million USD | 98.309% |
| Artelo Biosciences, Inc. | 20.42 Million USD | 84.9% |
| 2seventy bio, Inc. | 565.42 Million USD | 99.455% |
| ADMA Biologics, Inc. | 329.18 Million USD | 99.063% |
| Clene Inc. | 52.34 Million USD | 94.108% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | 94.749% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | 97.626% |
| GeoVax Labs, Inc. | 9.28 Million USD | 66.779% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 99.528% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | 97.023% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | 97.635% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | 96.839% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 95.656% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 98.729% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 99.843% |
| Evaxion Biotech A/S | 12.88 Million USD | 76.072% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 98.776% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 99.59% |
| Trevena, Inc. | 40.6 Million USD | 92.405% |
| Surrozen, Inc. | 46.08 Million USD | 93.307% |
| Tyra Biosciences, Inc. | 225.85 Million USD | 98.635% |
| Cingulate Inc. | 3.49 Million USD | 11.67% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | 81.454% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 95.305% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | 73.606% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 98.851% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 99.588% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | 97.55% |
| Clearmind Medicine Inc. | 4.32 Million USD | 28.684% |
| Kronos Bio, Inc. | 213.27 Million USD | 98.554% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | 98.07% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | 63.975% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 99.163% |
| Statera Biopharma, Inc. | 21.16 Million USD | 85.432% |
| ImmunityBio, Inc. | 504.45 Million USD | 99.389% |
| Korro Bio, Inc. | 221.66 Million USD | 98.609% |
| Kineta, Inc. | 10.28 Million USD | 70.003% |
| BioVie Inc. | 25.2 Million USD | 87.766% |
| Codexis, Inc. | 136.56 Million USD | 97.742% |
| Celularity Inc. | 143.88 Million USD | 97.857% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 99.515% |
| Celcuity Inc. | 191.21 Million USD | 98.387% |
| Virax Biolabs Group Limited | 5.48 Million USD | 43.764% |
| Cibus, Inc. | 544.41 Million USD | 99.434% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | 97.55% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 84.988% |
| IN8bio, Inc. | 33.7 Million USD | 90.851% |
| Kodiak Sciences Inc. | 479.37 Million USD | 99.357% |
| Annexon, Inc. | 297.67 Million USD | 98.964% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | 98.217% |
| Assembly Biosciences, Inc. | 137.46 Million USD | 97.757% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | 85.309% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 99.897% |
| Eyenovia, Inc. | 28.77 Million USD | 89.284% |
| Puma Biotechnology, Inc. | 230.52 Million USD | 98.662% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | 57.309% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | 94.938% |
| Arcellx, Inc. | 825.13 Million USD | 99.626% |
| Cardiff Oncology, Inc. | 81.63 Million USD | 96.222% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 99.333% |
| Regulus Therapeutics Inc. | 30.75 Million USD | 89.971% |
| Moolec Science SA | 24.05 Million USD | 87.177% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 99.006% |
| Geron Corporation | 394.07 Million USD | 99.217% |
| LAVA Therapeutics N.V. | 101.71 Million USD | 96.968% |
| Royalty Pharma plc | 16.38 Billion USD | 99.981% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 99.482% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | 55.91% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | 74.358% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | 98.636% |
| Humacyte, Inc. | 128.22 Million USD | 97.595% |
| Structure Therapeutics Inc. | 482.01 Million USD | 99.36% |
| 89bio, Inc. | 596.26 Million USD | 99.483% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 98.777% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -66.702% |
| Genelux Corporation | 27.89 Million USD | 88.944% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | 96.55% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | 98.656% |
| Notable Labs, Ltd. | 19.54 Million USD | 84.218% |
| Liquidia Corporation | 120.43 Million USD | 97.439% |
| Mustang Bio, Inc. | 17.74 Million USD | 82.618% |
| Immunovant, Inc. | 666.71 Million USD | 99.537% |
| Quantum-Si incorporated | 298.25 Million USD | 98.966% |
| Arbutus Biopharma Corporation | 144.4 Million USD | 97.864% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | 94.306% |
| Vera Therapeutics, Inc. | 175.54 Million USD | 98.243% |
| Acasti Pharma Inc. | 73.3 Million USD | 95.793% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | 32.254% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 88.192% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 99.68% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | 40.577% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | 86.462% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | 94.024% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | 98.293% |
| PepGen Inc. | 143.05 Million USD | 97.844% |
| Moleculin Biotech, Inc. | 38.21 Million USD | 91.93% |
| United Therapeutics Corporation | 7.16 Billion USD | 99.957% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | 83.925% |
| Solid Biosciences Inc. | 164.93 Million USD | 98.13% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | 47.482% |
| Immuneering Corporation | 102.58 Million USD | 96.994% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | 28.423% |
| Silo Pharma, Inc. | 7.74 Million USD | 60.187% |
| Belite Bio, Inc | 94.64 Million USD | 96.741% |
| XOMA Corporation | 234.3 Million USD | 98.684% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | 98.677% |
| Bionomics Limited | 27.64 Million USD | 88.846% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 99.232% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 97.128% |
| uniQure N.V. | 831.68 Million USD | 99.629% |
| Cassava Sciences, Inc. | 151.66 Million USD | 97.967% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | 30.762% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 98.874% |
| Forte Biosciences, Inc. | 38.98 Million USD | 92.088% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | 24.284% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | 91.627% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | 57.309% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | 12.212% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | 73.911% |
| Altimmune, Inc. | 210.64 Million USD | 98.536% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 99.604% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 97.128% |
| Compugen Ltd. | 121.33 Million USD | 97.458% |
| Peak Bio, Inc. | 2.59 Million USD | -18.779% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | 98.21% |
| Benitec Biopharma Inc. | 52.21 Million USD | 94.093% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 99.098% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | 91.131% |
| Zura Bio Limited | 100.84 Million USD | 96.942% |
| PolyPid Ltd. | 15.37 Million USD | 79.938% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | 97.415% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | 91.131% |
| Instil Bio, Inc. | 325.63 Million USD | 99.053% |
| argenx SE | 4.54 Billion USD | 99.932% |
| Immunome, Inc. | 148.54 Million USD | 97.924% |
| Compass Therapeutics, Inc. | 156.87 Million USD | 98.034% |
| Verona Pharma plc | 308.12 Million USD | 98.999% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | 96.454% |
| Shattuck Labs, Inc. | 159.56 Million USD | 98.067% |
| CervoMed Inc. | 9.97 Million USD | 69.075% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | 98.364% |
| Plus Therapeutics, Inc. | 11.38 Million USD | 72.919% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | 98.281% |
| Moolec Science SA | 24.05 Million USD | 87.177% |
| Enveric Biosciences, Inc. | 6.11 Million USD | 49.587% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | 98.217% |
| AnaptysBio, Inc. | 452.38 Million USD | 99.318% |
| Design Therapeutics, Inc. | 289.64 Million USD | 98.935% |
| Leap Therapeutics, Inc. | 72.82 Million USD | 95.765% |
| NeurAxis, Inc. | 509.49 Thousand USD | -505.299% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | 43.079% |
| Lumos Pharma, Inc. | 40.63 Million USD | 92.411% |
| Achilles Therapeutics plc | 161.45 Million USD | 98.09% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | 96.454% |
| 180 Life Sciences Corp. | 5.25 Million USD | 41.363% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | 95.621% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | 63.975% |
| Nutriband Inc. | 7.51 Million USD | 58.974% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 98.789% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | 98.453% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | 95.953% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | 94.675% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 99.414% |
| Palisade Bio, Inc. | 14.05 Million USD | 78.053% |
| Tourmaline Bio, Inc. | 210.29 Million USD | 98.533% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 99.789% |
| Neurogene Inc. | 222.57 Million USD | 98.614% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 99.523% |
| AEON Biopharma, Inc. | 6.84 Million USD | 54.945% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 99.319% |
| Sesen Bio, Inc. | 189.17 Million USD | 98.37% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 98.866% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | 77.509% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 99.605% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 98.845% |
| Athira Pharma, Inc. | 160.24 Million USD | 98.075% |
| Vaccinex, Inc. | 3.63 Million USD | 15.065% |
| HCW Biologics Inc. | 28.51 Million USD | 89.184% |
| XOMA Corporation | 234.3 Million USD | 98.684% |
| Nektar Therapeutics | 398.03 Million USD | 99.225% |
| Arvinas, Inc. | 1.3 Billion USD | 99.764% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | 81.899% |
| Merus N.V. | 458.49 Million USD | 99.327% |
| Omega Therapeutics, Inc. | 204.36 Million USD | 98.491% |
| Quince Therapeutics, Inc. | 180.2 Million USD | 98.289% |
| Rezolute, Inc. | 132.73 Million USD | 97.677% |
| Clene Inc. | 52.34 Million USD | 94.108% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | 79.335% |
| BeyondSpring Inc. | 24.8 Million USD | 87.569% |
| Synlogic, Inc. | 75.55 Million USD | 95.918% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | 74.001% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | 67.066% |
| Peak Bio, Inc. | 2.59 Million USD | -18.779% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | 98.236% |
| Krystal Biotech, Inc. | 818.35 Million USD | 99.623% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 98.717% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 99.575% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | 13.787% |
| MannKind Corporation | 475.19 Million USD | 99.351% |
| Ikena Oncology, Inc. | 192.09 Million USD | 98.395% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | 76.94% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | 97.354% |
| Gossamer Bio, Inc. | 311.91 Million USD | 99.011% |
| CohBar, Inc. | 16.36 Million USD | 81.156% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | 91.229% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | 57.84% |
| Legend Biotech Corporation | 1.84 Billion USD | 99.833% |
| Mural Oncology plc | 301.74 Million USD | 98.978% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 90.12% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | 45.708% |
| Disc Medicine, Inc. | 367.99 Million USD | 99.162% |
| Champions Oncology, Inc. | 26.13 Million USD | 88.198% |
| REGENXBIO Inc. | 573.97 Million USD | 99.463% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -13.881% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 98.002% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | 74.461% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 99.093% |
| Vaxart, Inc. | 91.83 Million USD | 96.642% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | 94.852% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | 97.921% |
| Cellectis S.A. | 334.27 Million USD | 99.077% |
| Longeveron Inc. | 12.17 Million USD | 74.676% |
| Repare Therapeutics Inc. | 253.9 Million USD | 98.785% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 99.906% |
| Inozyme Pharma, Inc. | 200.84 Million USD | 98.465% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 99.852% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -89.784% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 98.889% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | 98.109% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | 97.777% |
| Anixa Biosciences, Inc. | 25.52 Million USD | 87.916% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.986% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 99.733% |
| Revelation Biosciences, Inc. | 12.21 Million USD | 74.748% |
| Veru Inc. | 50.59 Million USD | 93.905% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | 93.23% |
| Cingulate Inc. | 3.49 Million USD | 11.67% |
| Passage Bio, Inc. | 150.54 Million USD | 97.951% |
| Context Therapeutics Inc. | 16.06 Million USD | 80.8% |
| Exicure, Inc. | 11.58 Million USD | 73.368% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 99.18% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | 98.092% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | 82.349% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 99.073% |
| Nuvalent, Inc. | 732.38 Million USD | 99.579% |
| ABVC BioPharma, Inc. | 14.94 Million USD | 79.363% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | 96.556% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | 78.268% |
| OmniAb, Inc. | 401.98 Million USD | 99.233% |
| Anew Medical, Inc. | 19.45 Million USD | 84.149% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | 88.461% |
| Lipocine Inc. | 23 Million USD | 86.592% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | 97.794% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 98.991% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 96.326% |
| G1 Therapeutics, Inc. | 121.54 Million USD | 97.463% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | 61.134% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 99.65% |
| Ocugen, Inc. | 64.54 Million USD | 95.222% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | 97.524% |
| Q32 Bio Inc. | 306.11 Million USD | 98.993% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | 26.711% |
| Alumis Inc. Common Stock | 89.61 Million USD | 96.559% |
| Equillium, Inc. | 50.53 Million USD | 93.897% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | 95.899% |
| Coya Therapeutics, Inc. | 41.27 Million USD | 92.528% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -81.32% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 88.202% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 95.214% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | 17.255% |
| Dominari Holdings Inc. | 57.55 Million USD | 94.642% |
| Edesa Biotech, Inc. | 8.89 Million USD | 65.311% |
| vTv Therapeutics Inc. | 11.01 Million USD | 72.01% |
| Bio-Techne Corporation | 2.81 Billion USD | 99.89% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 99.671% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 99.62% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 98.889% |
| Candel Therapeutics, Inc. | 41.7 Million USD | 92.605% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 99.538% |
| Nkarta, Inc. | 378.88 Million USD | 99.186% |
| BioCardia, Inc. | 2.98 Million USD | -3.247% |
| Iterum Therapeutics plc | 26.25 Million USD | 88.256% |